Australia's most trusted
source of pharma news
Saturday, 18 October 2025
Posted 17 October 2025 AM
In a major breakthrough in the way medicines are funded in Australia, the PBAC has recommended a broad listing for BMS' immunotherapy drugs Opdivo and Yervoy in advanced or metastatic cancers.
The PBAC said its history-making decision to recommend a multi-indication listing followed a revised proposal from BMS which ensured the financial risk was contained within a risk-sharing arrangement.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.